Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views

Last Hour:
Last 24 Hours:

M Pharmaceutical continues to make good progress with pipeline

Thursday, October 27, 2016 8:17
% of readers think this story is Fact. Add your two cents.

M Pharmaceutical Inc (CNSX:MQ) has employed Camargo Pharmaceutical Services to speed up the clinical trials process for C-103, its recently acquired reformulated orlistat drug technology.

Camargo Pharmaceutical Services is an experienced global strategist providing comprehensive drug development services specialized for the 505(b)(2) new drug application approval pathway and analogous European processes.

“At this exciting and critical stage in the development of C-103, our leadership team and Advisory Board believe it is prudent to engage Camargo’s guidance and expertise,” the company said.

C-103 is intended to maintain the efficacy of orlistat while minimizing its socially unacceptable side effects.

In an update for shareholders, the company said it continues to make good progress with its product pipeline.

Story by ProactiveInvestors


We encourage you to Share our Reports, Analyses, Breaking News and Videos. Simply Click your Favorite Social Media Button and Share.

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Top Global

Top Alternative




Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.